Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 78

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 78
---
 - 4.57%3.27% - 4.33%1.87% - 3.70%As of December 31, 2024, the total unrecognized compensation expense was approximately $37.4 million. The Company expects to prospectively recognize these expenses over a weighted-average period of 2.5 years.Restricted Stock UnitsThe following table summarizes restricted stock unit (RSU) activities:Number ofRSUsWeighted-AverageGrant Date Fair Value per ShareNonvested, December 31, 2022131,960 $32.17 Granted227,980 $38.60 Vested(47,049)$32.18 Forfeited(12,750)$35.68 Nonvested, December 31, 2023300,141 $36.90 Granted198,414 $28.06 Vested(100,891)$36.51 Forfeited(19,499)$34.71 Nonvested, December 31, 2024378,165 $32.48 The total aggregate grant date fair value of RSUs that vested during the years ended December 31, 2024, 2023, and 2022 were $3.7 million, $1.5 million, and $0.6 million, respectively.As of December 31, 2024, the total unrecognized compensation expense was $8.4 million. The Company expects to prospectively recognize these expenses over a weighted-average period of 2.4 years. 

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)9. Share-Based Payments (Continued)

Performance Stock Units The following table summarizes performance share unit (PSU) activities:Performance-Based PSUsMarket-Based UnitsTotal PSUsNumber of PSUsWeighted-AverageGrant Date Fair Value per ShareNumber of PSUsWeighted-AverageGrant Date Fair Value per ShareNumber of PSUsWeighted-AverageGrant Date Fair Value per ShareNonvested, December 31, 2022181,750 $29.07 20,000 $28.63 201,750 $29.03 Granted205,000 $34.00 — $— 205,000 $34.00 Vested(132,120)$30.72 — $— (132,120)$30.72 Forfeited(